Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04800237 · ClinicalTrials.gov registry record · Phase 2
Evaluating the Effects of VQW-765 vs. Placebo in Performance Anxiety
A Phase 2 study of Performance Anxiety, sponsored by Vanda Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 230
- Enrollment target
- 15
- Study locations
NCT04800237: Completed Phase 2 study of Performance Anxiety, sponsored by Vanda Pharmaceuticals.
NCT04800237 is a Phase 2 study of Performance Anxiety that has completed, run by Vanda Pharmaceuticals. The registered enrollment target is 230 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% higher). The trial reports 15 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04800237, a Phase 2 study of Performance Anxiety, has completed, sponsored by Vanda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 230 participants
- Enrollment target
- 15
- Study locations
Study Summary
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single oral dose of VQW-765 compared to placebo in male and female participants with performance anxiety.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VQW-765
Study Locations (15)
California
- Vanda Investigational Site - Beverly Hills
- Vanda Investigational Site - Garden Grove
- Vanda Investigational Site - San Jose
- Vanda Investigational Site - Torrance
Massachusetts
- Vanda Investigational Site - Boston
- Vanda Investigational Site - North Dartmouth
New York
- Vanda Investigational Site - New York
- Vanda Investigational Site - Staten Island
Arizona
- Vanda Investigational Site - Tempe
Florida
- Vanda Investigational Site - Orlando
Nevada
- Vanda Investigational Site - Las Vegas
New Jersey
- Vanda Investigational Site - Berlin
North Carolina
- Vanda Investigational Site - Raleigh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2021-02-23 |
| Est. Completion | 2022-08-02 |
| Phase | Phase 2 |
What the finished NCT04800237 record still lists
NCT04800237 is an interventional study that assigns participants to a tested intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% higher).
The record links to 1 condition, with Performance Anxiety appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04800237 lists 15 locations in 10 states (California, Massachusetts, New York).
Frequently Asked Questions
What is clinical trial NCT04800237 about?
NCT04800237 is a clinical study titled "Evaluating the Effects of VQW-765 vs. Placebo in Performance Anxiety". This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single oral dose of VQW-765 compared to placebo in male and female participants with performance anxiety.
What is the current status of trial NCT04800237?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 230 participants. The study started on 2021-02-23. Estimated completion is 2022-08-02.
What conditions does trial NCT04800237 study?
This clinical trial studies the following conditions: Performance Anxiety.
What interventions are being tested in trial NCT04800237?
The interventions under investigation include: Placebo (DRUG), VQW-765 (DRUG).
Who is sponsoring clinical trial NCT04800237?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04800237 being conducted?
This trial has 15 study locations across Arizona, California, Florida, Massachusetts, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Performance Anxiety
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04800237's enrollment target sits among peer trials
230 257th of 2000 higher than 1,737 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI